Patents by Inventor Arthur Clapp

Arthur Clapp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Systems for treating dermal inflammatory conditions
    Patent number: 11590211
    Abstract: The present invention is directed to novel systems and methods for treating dermal inflammatory disorders, such as psoriasis.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: February 28, 2023
    Assignee: Nuvothera, Inc.
    Inventor: Arthur Clapp
  • SYSTEMS FOR TREATING DERMAL INFLAMMATORY CONDITIONS
    Publication number: 20210046166
    Abstract: The present invention is directed to novel systems and methods for treating dermal inflammatory disorders, such as psoriasis.
    Type: Application
    Filed: October 12, 2020
    Publication date: February 18, 2021
    Inventor: Arthur Clapp
  • Systems for treating dermal inflammatory conditions
    Patent number: 10835584
    Abstract: The present invention is directed to novel systems and methods for treating dermal inflammatory disorders, such as psoriasis.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: November 17, 2020
    Assignee: Nuvothera, Inc.
    Inventor: Arthur Clapp
  • SYSTEMS FOR TREATING DERMAL INFLAMMATORY CONDITIONS
    Publication number: 20170360903
    Abstract: The present invention is directed to novel systems and methods for treating dermal inflammatory disorders, such as psoriasis.
    Type: Application
    Filed: June 16, 2017
    Publication date: December 21, 2017
    Inventor: Arthur Clapp
  • Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
    Patent number: 9744168
    Abstract: The present invention relates to a method of reducing cutaneous facial flushing caused by systemic use of phosphodiesterase type 5 (PDE5) inhibitors by topical facial dermatological application of an effective dose of a composition comprising at least one alpha adrenergic receptor agonist.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: August 29, 2017
    Assignee: GALDERMA LABORATORIES, INC.
    Inventors: Warren J. Scherer, Arthur Clapp, Philippe Andres
  • Method of Reducing Facial Flushing Associated with Systemic Use of Phosphodiesterase Type 5 Inhibitors
    Publication number: 20140343067
    Abstract: The present invention relates to a method of reducing cutaneous facial flushing caused by systemic use of phosphodiesterase type 5 (PDE5) inhibitors by topical facial dermatological application of an effective dose of a composition comprising at least one alpha adrenergic receptor agonist.
    Type: Application
    Filed: October 12, 2012
    Publication date: November 20, 2014
    Inventors: Warren J. Scherer, Arthur Clapp, Philippe Andres